OBJECTIVES: CD44 is a promising target for therapy in head and neck squamous cell carcinoma (HNSCC) and has two defined roles in tumorigenesis: it is a cancer stem cell (CSC) marker and it promotes migration and proliferation through interaction with many signaling molecules. The purpose of this study was to investigate the role of CD44 in HNSCC carcinogenesis. MATERIALS AND METHODS: The effects of CD44 in cell proliferation, migration, apoptosis and cisplatin resistance were studied by its overexpression in HNSCC cells. We also evaluated the effect of CD44 on tumor progression by siRNA methodology, immunohistochemistry (IHC) and western blot analysis. CD44 and EGFR colocalization were examined in CAL 27 cells by laser scanning confocal microscopy. The interaction between CD44 and EGFR was analyzed by immunoprecipation. RESULTS: Overexpression of CD44 enhances cell proliferation and migration and correlates with increased cisplatin resistance and apoptosis inhibition in SCC25 cells. Downregulation of CD44 in CAL27 cells inhibited constitutive EGFR phosphorylation and significantly reduced tumor growth in nude mice. CD44 and EGFR colocalized in CAL 27 cells. CD44 coimmunoprecipated with EGFR in CAL 27 cells, indicating that these proteins interact with each other. CONCLUSION: CD44 therapy in HNSCC may target the CSC population and alter EGFR signaling.
OBJECTIVES:CD44 is a promising target for therapy in head and neck squamous cell carcinoma (HNSCC) and has two defined roles in tumorigenesis: it is a cancer stem cell (CSC) marker and it promotes migration and proliferation through interaction with many signaling molecules. The purpose of this study was to investigate the role of CD44 in HNSCC carcinogenesis. MATERIALS AND METHODS: The effects of CD44 in cell proliferation, migration, apoptosis and cisplatin resistance were studied by its overexpression in HNSCC cells. We also evaluated the effect of CD44 on tumor progression by siRNA methodology, immunohistochemistry (IHC) and western blot analysis. CD44 and EGFR colocalization were examined in CAL 27 cells by laser scanning confocal microscopy. The interaction between CD44 and EGFR was analyzed by immunoprecipation. RESULTS: Overexpression of CD44 enhances cell proliferation and migration and correlates with increased cisplatin resistance and apoptosis inhibition in SCC25 cells. Downregulation of CD44 in CAL27 cells inhibited constitutive EGFR phosphorylation and significantly reduced tumor growth in nude mice. CD44 and EGFR colocalized in CAL 27 cells. CD44 coimmunoprecipated with EGFR in CAL 27 cells, indicating that these proteins interact with each other. CONCLUSION:CD44 therapy in HNSCC may target the CSC population and alter EGFR signaling.
Authors: H Morrison; L S Sherman; J Legg; F Banine; C Isacke; C A Haipek; D H Gutmann; H Ponta; P Herrlich Journal: Genes Dev Date: 2001-04-15 Impact factor: 11.361
Authors: Elizabeth J Franzmann; Erika P Reategui; Lutecia H Mateus Pereira; Felipe Pedroso; Debbie Joseph; Glenn O Allen; Kara Hamilton; Isildinha Reis; Robert Duncan; W Jarrard Goodwin; Jennifer J Hu; Vinata B Lokeshwar Journal: Head Neck Date: 2011-07-11 Impact factor: 3.147
Authors: Lutécia H Mateus Pereira; Islamiyat Nancy Adebisi; Aymee Perez; Michael Wiebel; Isildinha Reis; Robert Duncan; W Jarrard Goodwin; Jennifer J Hu; Vinata B Lokeshwar; Elizabeth J Franzmann Journal: Cancer Biomark Date: 2011 Impact factor: 4.388
Authors: Annett Hölsken; Christina Stache; Sven Martin Schlaffer; Jörg Flitsch; Rudolf Fahlbusch; Michael Buchfelder; Rolf Buslei Journal: Pituitary Date: 2014-12 Impact factor: 4.107
Authors: L J Melchers; M J A M Clausen; M F Mastik; L Slagter-Menkema; J E van der Wal; G B A Wisman; J L N Roodenburg; E Schuuring Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Lutécia H Mateus Pereira; Isildinha M Reis; Erika P Reategui; Claudia Gordon; Sandra Saint-Victor; Robert Duncan; Carmen Gomez; Stephanie Bayers; Penelope Fisher; Aymee Perez; W Jarrard Goodwin; Jennifer J Hu; Elizabeth J Franzmann Journal: Cancer Prev Res (Phila) Date: 2016-03-28